- Home
- MYI vs TERN Comparison
MYI vs TERN Comparison
Compare MYI & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYI
- TERN
- Stock Information
- Founded
- MYI 1992
- TERN 2017
- Country
- MYI United States
- TERN United States
- Employees
- MYI N/A
- TERN N/A
- Industry
- MYI Investment Bankers/Brokers/Service
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- MYI Finance
- TERN Health Care
- Exchange
- MYI Nasdaq
- TERN Nasdaq
- Market Cap
- MYI 701.9M
- TERN 634.5M
- IPO Year
- MYI N/A
- TERN 2021
- Fundamental
- Price
- MYI $11.07
- TERN $7.13
- Analyst Decision
- MYI
- TERN Buy
- Analyst Count
- MYI 0
- TERN 6
- Target Price
- MYI N/A
- TERN $13.99
- AVG Volume (30 Days)
- MYI 256.7K
- TERN 1.1M
- Earning Date
- MYI 01-01-0001
- TERN 11-11-2025
- Dividend Yield
- MYI 4.81%
- TERN N/A
- EPS Growth
- MYI N/A
- TERN N/A
- EPS
- MYI N/A
- TERN N/A
- Revenue
- MYI N/A
- TERN N/A
- Revenue This Year
- MYI N/A
- TERN N/A
- Revenue Next Year
- MYI N/A
- TERN N/A
- P/E Ratio
- MYI N/A
- TERN N/A
- Revenue Growth
- MYI N/A
- TERN N/A
- 52 Week Low
- MYI $9.32
- TERN $1.87
- 52 Week High
- MYI $11.70
- TERN $10.70
- Technical
- Relative Strength Index (RSI)
- MYI 79.90
- TERN 54.96
- Support Level
- MYI $10.54
- TERN $6.78
- Resistance Level
- MYI $10.60
- TERN $7.67
- Average True Range (ATR)
- MYI 0.08
- TERN 0.43
- MACD
- MYI 0.05
- TERN -0.06
- Stochastic Oscillator
- MYI 100.00
- TERN 39.81
About MYI Blackrock MuniYield Quality Fund III Inc
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.